Articles with public access mandates - Deirdre WeymannLearn more
Not available anywhere: 5
Pan-cancer analysis of advanced patient tumors reveals interactions between therapy and genomic landscapes
E Pleasance, E Titmuss, L Williamson, H Kwan, L Culibrk, EY Zhao, ...
Nature Cancer 1 (4), 452-468, 2020
Mandates: US National Institutes of Health, Canadian Institutes of Health Research …
Economic evaluations of next-generation precision oncology: a critical review
D Weymann, R Pataky, DA Regier
JCO Precision Oncology 2, 1-23, 2018
Mandates: Canadian Cancer Society
Patterns, predictors and persistence of chronic sedative use: a population-based observational study of older adults in British Columbia, Canada
SG Morgan, D Weymann
European journal of clinical pharmacology 73, 1001-1008, 2017
Mandates: Canadian Institutes of Health Research
Oral opioid use during vaginal delivery hospitalizations
M Mourad, R Landau, JD Wright, Z Siddiq, CR Duffy, AR Kern-Goldberger, ...
American Journal of Perinatology 37 (04), 390-397, 2020
Mandates: US National Institutes of Health
Economic evaluation of rare diseases and the diagnostic odyssey
DA Regier, D Weymann, I Cromwell, M Ehman, S Pollard
Economic Evaluation in Genomic and Precision Medicine, 47-70, 2023
Mandates: Genome Canada
Available somewhere: 26
Frequency and cost of potentially inappropriate prescribing for older adults: a cross-sectional study
SG Morgan, J Hunt, J Rioux, J Proulx, D Weymann, C Tannenbaum
Canadian Medical Association Open Access Journal 4 (2), E346-E351, 2016
Mandates: Canadian Institutes of Health Research
Sex differences in the risk of receiving potentially inappropriate prescriptions among older adults
SG Morgan, D Weymann, B Pratt, K Smolina, EJ Gladstone, C Raymond, ...
Age and ageing 45 (4), 535-542, 2016
Mandates: Canadian Institutes of Health Research
Whole-genome and transcriptome analysis enhances precision cancer treatment options
E Pleasance, A Bohm, LM Williamson, JMT Nelson, Y Shen, M Bonakdar, ...
Annals of Oncology 33 (9), 939-949, 2022
Mandates: US National Institutes of Health, Genome Canada, Natural Sciences and …
The cost and cost trajectory of whole‐genome analysis guiding treatment of patients with advanced cancers
D Weymann, J Laskin, R Roscoe, KA Schrader, S Chia, S Yip, ...
Molecular genetics & genomic medicine 5 (3), 251-260, 2017
Mandates: Canadian Cancer Society
Valuation of health and nonhealth outcomes from next-generation sequencing: approaches, challenges, and solutions
DA Regier, D Weymann, J Buchanan, DA Marshall, S Wordsworth
Value in Health 21 (9), 1043-1047, 2018
Mandates: Canadian Cancer Society
Geographic variations in prescription opioid dispensations and deaths among women and men in British Columbia, Canada
EJ Gladstone, K Smolina, D Weymann, K Rutherford, SG Morgan
Medical Care 53 (11), 954-959, 2015
Mandates: Canadian Institutes of Health Research
Toward the diagnosis of rare childhood genetic diseases: what do parents value most?
S Pollard, D Weymann, J Dunne, F Mayanloo, J Buckell, J Buchanan, ...
European Journal of Human Genetics 29 (10), 1491-1501, 2021
Mandates: Genome Canada
A perspective on life-cycle health technology assessment and real-world evidence for precision oncology in Canada
DA Regier, S Pollard, M McPhail, T Bubela, TP Hanna, C Ho, HJ Lim, ...
NPJ Precision Oncology 6 (1), 76, 2022
Mandates: Canadian Cancer Society, Genome Canada
Long-term sedative use among community-dwelling adults: a population-based analysis
D Weymann, EJ Gladstone, K Smolina, SG Morgan
Canadian Medical Association Open Access Journal 5 (1), E52-E60, 2017
Mandates: Canadian Institutes of Health Research
Allocating healthcare resources to genomic testing in Canada: latest evidence and current challenges
D Weymann, N Dragojlovic, S Pollard, DA Regier
Journal of community genetics 13 (5), 467-476, 2022
Mandates: Canadian Cancer Society
Genetic testing for hereditary cancer syndromes: patient recommendations for improved risk communication
S Pollard, S Kalloger, D Weymann, S Sun, J Nuk, KA Schrader, DA Regier
Health Expectations 23 (4), 884-892, 2020
Mandates: Canadian Cancer Society, Canadian Institutes of Health Research
Matching methods in precision oncology: An introduction and illustrative example
D Weymann, J Laskin, SJM Jones, H Lim, DJ Renouf, R Roscoe, ...
Molecular Genetics & Genomic Medicine 9 (1), e1554, 2021
Mandates: Canadian Institutes of Health Research, Genome Canada, Natural Sciences and …
Patient preferences for massively parallel sequencing genetic testing of colorectal cancer risk: a discrete choice experiment
D Weymann, DL Veenstra, GP Jarvik, DA Regier
European Journal of Human Genetics 26 (9), 1257-1265, 2018
Mandates: US National Institutes of Health
Defining a core data set for the economic evaluation of precision oncology
S Pollard, D Weymann, B Chan, M Ehman, S Wordsworth, J Buchanan, ...
Value in Health 25 (8), 1371-1380, 2022
Mandates: Genome Canada
Clinical and cost outcomes following genomics‐informed treatment for advanced cancers
D Weymann, S Pollard, B Chan, E Titmuss, A Bohm, J Laskin, SJM Jones, ...
Cancer Medicine 10 (15), 5131-5140, 2021
Mandates: US National Institutes of Health, Genome Canada, Natural Sciences and …
Publication and funding information is determined automatically by a computer program